Tiziana Life Sciences Ltd (TLSA) Stock Price, Quote & News

Company Profile

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R mono...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: www.tizianalifesciences.com

Address:

14/15 Conduit Street, London, United Kingdom

Fedrano175 Sep. 21 at 6:08 PM

$TLSA as i told you! The most important thing from next week the database Is lock..so from that Moment the Trail Is unblinded and then the news can arrive in Every moment!

0 · Reply

hopedoesntGAF Sep. 21 at 5:38 PM

$TLSA Just a couple of weeks away... I would warn shorts, but nobody is dumb enough to short this.

0 · Reply

Iceman89 Sep. 21 at 5:09 PM

$TLSA Really like those PR updates, the company knows that the stock price is unfairly low and tells investors to just keep hanging on for a little bit more. Yes, I can hang on.

1 · Reply

AlphaBull_10M Sep. 21 at 1:20 PM

*** WARNING *** Market is a total bubble scam that is manipulated by blind bulltards and is due for a huge correction, therefore, everyone should sell everything (WINNERS) and only buy (BIG LOSERS): JD, LULU, ZTS, PYPL, EL - says Michael Burry. LOL $MU $NVDA $SOXX $NBIS $TLSA

2 · Reply

Tradephoenix Sep. 21 at 11:09 AM

$TLSA https://x.com/tizianals/status/2101989827566854636?s=46&t=HqWhscg92m9uV_YSVozALA 🔥

1 · Reply

rp6577 Sep. 21 at 11:02 AM

$TLSA buckle up 🔥

0 · Reply

weather Sep. 21 at 9:18 AM

$TLSA the shorts have managed to give us longs one day off

1 · Reply

rp6577 Sep. 19 at 8:04 AM

$TLSA worth noting that RRMS accounts for the vast majority of all multiple sclerosis patients. Tiziana and KAIMRC intend to evaluate intranasal foralumab in combination with existing anti-CD20 therapies for RRMS patients who are responding poorly to standard treatment. Proving efficacy via the October data will force the market to re-rate Tiziana from a niche na-SPMS developer into a platform company actively addressing the entire global MS market. But also don’t forget the other indications- MSA, traumatic brain injury and Alzheimer’s! Just a huge opportunity here $XBI $LABU

3 · Reply

KentTwitThis Sep. 18 at 10:43 PM

$TLSA new MUA in place and CEO has bought 1 million shares in the past few months. Data comes out next month. Coincidence??? I think not!

1 · Reply

JuggernautRaider Sep. 18 at 3:24 PM

$SPCX let there be light 🚀 ⚡️ $TSLA what is you doing https://www.linkedin.com/posts/jeff-conroy-80a39323_dear-tesla-tesla-energy-tesla-india-you-activity-7503412907586637824-CGft Buy $TLSA and $ALT tiziana life science of italy and pemvituvide long for the win 🏆 🇮🇹 🍱 🇺🇸 🇵🇱 ☮️ 🚀

1 · Reply

Tiziana Life Sciences announces last patient completed Phase 2a INFORM-MS trial

2026-09-17T11:15:25.000Z - 4 days ago

Tiziana Life Sciences signs MOU with KAIMRC in Saudi Arabia

2026-09-03T10:00:10.000Z - 18 days ago

Tiziana Life Sciences initiated with a Buy at BTIG

Aug 24, 2026, 7:00 AM EDT - 4 weeks ago

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

2026-08-06T13:16:44.000Z - 6 weeks ago

Tiziana Life Sciences CEO Ivor Elrifi purchases 321,423 shares

Aug 4, 2026, 7:00 AM EDT - 6 weeks ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Jul 31, 2026, 7:00 AM EDT - 7 weeks ago

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

2026-07-22T11:30:23.000Z - 2 months ago

Tiziana Life Sciences chairman Gabriele Cerrone purchases 42,357 shares at 99c

Jul 22, 2026, 7:00 AM EDT - 2 months ago

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

2026-06-25T11:20:37.000Z - 2 months ago

Tiziana Life Sciences doses last patient in intranasal foralumab trial

Jun 25, 2026, 7:00 AM EDT - 2 months ago

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

2026-06-15T11:42:42.000Z - 3 months ago

Tiziana Life Sciences chairman Gabriele Cerrone purchases 15,000 shares

May 28, 2026, 7:00 AM EDT - 3 months ago

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

2026-05-21T15:05:09.000Z - 4 months ago

Tiziana fully enrolls Phase 2 placebo-controlled MS trial

May 21, 2026, 11:00 AM EDT - 4 months ago

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

2026-05-19T12:13:28.000Z - 4 months ago

Tiziana Life Sciences announces updated intranasal foralumab data

May 19, 2026, 7:00 AM EDT - 4 months ago

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

2026-05-14T13:46:05.000Z - 4 months ago

Tiziana Phase 2 trial for foralumab shows reduced brain inflammation

May 14, 2026, 7:00 AM EDT - 4 months ago

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

2026-04-16T12:01:24.000Z - 5 months ago

Tiziana Life announces publication of preclinical data in bioRxiv preprint

Apr 16, 2026, 7:00 AM EDT - 5 months ago

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Apr 14, 2026, 7:00 AM EDT - 5 months ago

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

Apr 1, 2026, 7:00 AM EDT - 5 months ago

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

2026-02-25T12:25:15.000Z - 6 months ago

Tiziana Life Sciences announces new data on nasal foralumab

Feb 25, 2026, 7:00 AM EST - 6 months ago

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

2026-01-20T16:20:10.000Z - 8 months ago

Tiziana Life Sciences announces publication of intranasal foralumab results

Jan 20, 2026, 11:15 AM EST - 8 months ago

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Jan 16, 2026, 2:45 PM EST - 8 months ago

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

2026-01-16T12:05:16.000Z - 8 months ago

Tiziana Life Sciences prices 6.4M shares at $1.25 in registered direct offering

Jan 16, 2026, 7:00 AM EST - 8 months ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Jan 9, 2026, 7:00 AM EST - 8 months ago

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

2025-12-29T13:15:44.000Z - 8 months ago

Tiziana Life Sciences files annual safety report for intranasal foralumab

Dec 29, 2025, 8:00 AM EST - 8 months ago

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

2025-12-19T16:05:39.000Z - 9 months ago

Tiziana Life Sciences Chairman raises stake to 36% with acquisition of shares

Dec 19, 2025, 11:00 AM EST - 9 months ago

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Dec 17, 2025, 10:00 AM EST - 9 months ago

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

2025-12-17T13:50:17.000Z - 9 months ago

Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s trial

Dec 17, 2025, 8:45 AM EST - 9 months ago

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

2025-12-15T20:15:08.000Z - 9 months ago

Tiziana Life Sciences CEO Ivor Elrifi purchases 163,400 shares

2025-12-15T12:35:32.000Z - 9 months ago

Tiziana Life Sciences announces withdrawal of proposed public offering

Dec 15, 2025, 7:30 AM EST - 9 months ago

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

Dec 12, 2025, 2:10 PM EST - 9 months ago

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

Dec 2, 2025, 7:00 AM EST - 9 months ago

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

Nov 25, 2025, 8:30 AM EST - 10 months ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Nov 13, 2025, 8:30 AM EST - 10 months ago

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Oct 29, 2025, 7:00 AM EDT - 10 months ago

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Sep 30, 2025, 8:30 AM EDT - 11 months ago

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Sep 24, 2025, 8:30 AM EDT - 12 months ago

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Sep 15, 2025, 8:00 AM EDT - 1 year ago

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Sep 5, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 1 year ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Jul 21, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jun 13, 2025, 10:30 AM EDT - 1 year ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the Bio International Convention

May 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 1 year ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 9, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 6, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 4, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Feb 27, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 21, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 18, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Fedrano175 Sep. 21 at 6:08 PM

$TLSA as i told you! The most important thing from next week the database Is lock..so from that Moment the Trail Is unblinded and then the news can arrive in Every moment!

0 · Reply

hopedoesntGAF Sep. 21 at 5:38 PM

$TLSA Just a couple of weeks away... I would warn shorts, but nobody is dumb enough to short this.

0 · Reply

Iceman89 Sep. 21 at 5:09 PM

$TLSA Really like those PR updates, the company knows that the stock price is unfairly low and tells investors to just keep hanging on for a little bit more. Yes, I can hang on.

1 · Reply

AlphaBull_10M Sep. 21 at 1:20 PM

2 · Reply

Tradephoenix Sep. 21 at 11:09 AM

$TLSA https://x.com/tizianals/status/2101989827566854636?s=46&t=HqWhscg92m9uV_YSVozALA 🔥

1 · Reply

rp6577 Sep. 21 at 11:02 AM

$TLSA buckle up 🔥

0 · Reply

weather Sep. 21 at 9:18 AM

$TLSA the shorts have managed to give us longs one day off

1 · Reply

rp6577 Sep. 19 at 8:04 AM

3 · Reply

KentTwitThis Sep. 18 at 10:43 PM

$TLSA new MUA in place and CEO has bought 1 million shares in the past few months. Data comes out next month. Coincidence??? I think not!

1 · Reply

JuggernautRaider Sep. 18 at 3:24 PM

1 · Reply

JuggernautRaider Sep. 18 at 3:03 PM

$CGTX $TLSA $VYGR i love them all and keep buying dips! 🧠 beep beep @Biotech_Beast beep beep @Night_Owl_Biotech and hey you @Proposition_Joe BEEP BEEP $TNXP is undervalued too move over 🛻

0 · Reply

weather Sep. 18 at 2:26 PM

$TLSA well that did not last very long

2 · Reply

weather Sep. 18 at 10:54 AM

$TLSA at last the company has responded to market conditions- let's see where this action takes us

1 · Reply

Gegau001 Sep. 18 at 10:26 AM

$TLSA Let's have another wonderful and successful day 🍀👍😀✌️

1 · Reply

hopedoesntGAF Sep. 17 at 8:56 PM

$TLSA Great day... EXTREMELY

0 · Reply

rp6577 Sep. 17 at 8:00 PM

$TLSA great close

0 · Reply

Iceman89 Sep. 17 at 5:24 PM

$TLSA You know, respect to Ivor for travelling during non-peaceful times in the region and closing the deal. Clearly he cares about the company

0 · Reply

BioRich Sep. 17 at 5:17 PM

$TLSA Beautiful. Big news today.

0 · Reply

Varus_q Sep. 17 at 3:43 PM

A small but easy-to-miss detail in today’s news: $TLSA updated the Phase 2 topline timing to October, narrowing the previous guidance of late Q3/early Q4.

0 · Reply

rp6577 Sep. 17 at 1:47 PM

$TLSA huge volume to start the day 🔥 $XBI

0 · Reply

RTPRwire Sep. 17 at 1:46 PM

$TLSA is active on clinical trial results following a Globe Newswire release. Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center RTPR pushed this release out to users at 7:00:00 AM ET

0 · Reply

hopedoesntGAF Sep. 17 at 1:39 PM

$TLSA Would love to see the Saudis 🇸🇦 start buying shares....lol Don't be surprsied....

1 · Reply

Market Cap	115.25M
Revenue (ttm)	0.00
Net Income (ttm)	-18.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	534,900
Avg Vol	745,894
Day's Range	N/A - N/A
Shares Out	127.26M
Stochastic %K	57%
Beta	0.52
Analysts	Strong Sell
Price Target	$8.00